People: Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

2.93USD
9 Jul 2014
Price Change (% chg)

$-0.01 (-0.34%)
Prev Close
$2.94
Open
$2.93
Day's High
$3.04
Day's Low
$2.86
Volume
489,893
Avg. Vol
942,813
52-wk High
$7.77
52-wk Low
$1.27

Search Stocks

Scarlett, John 

Brief Biography

Dr. John A. Scarlett, M.D., is President, Chief Executive Officer, Director of Geron Corporation. He has served as Chief Executive Officer and a director since September 2011 and President since January 2012.Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately-held oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned subsidiary of Novo Nordisk A/S. Dr. Scarlett holds a B.A. in chemistry from Earlham College and an M.D. from the University of Chicago, Pritzker School of Medicine.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
589,600 -- 755,353 1,344,950

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Hoyoung Huh

--

John Scarlett

1,344,950

Olivia Bloom

578,818

Stephen Rosenfield

1,187,280

Andrew Grethlein

801,606

Melissa Kelly Behrs

830,707
As Of 30 Dec 2012
Search Stocks